


REMARKS

Claims 18 and 20 have been amended by physically inserting therein the structure of formula I and the associated definitions taken from claim 17. On final review of these claims prior to paying the issue fee, it was noted that independent method claims 17, 18 and 20 all referred to "the quinazoline derivative of formula I," but the structure and definitions of formula I were recited only in claim 17. Therefore, for completeness of the claims, the structure of formula I and the associated definitions have been exactly copied from claim 17, and inserted in each of claims 18 and 20.

This amendment does not, and is not intended to, change the scope or substance of claims 18 and 20 in any respect and is being made for purposes of clarification and completeness. It is believed that the review and entry of this amendment does not require any significant effort on the part of the Examiner. Accordingly, it is appropriate to make this amendment after allowance, and entry of the same is respectfully requested.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP


Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: December 17, 2004
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By: